Press coverage about Eli Lilly and (NASDAQ:LLY
) has been trending somewhat positive on Tuesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eli Lilly and earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.621588882543 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Eli Lilly and (NASDAQ LLY
) traded down 0.1059% during midday trading on Tuesday, reaching $78.7565. The company had a trading volume of 582,936 shares. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72. The company has a 50 day moving average of $81.83 and a 200 day moving average of $81.93. The firm has a market capitalization of $83.09 billion and a price-to-earnings ratio of 34.0790.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and (LLY ) Getting Somewhat Favorable Media Coverage, Analysis Finds” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/eli-lilly-and-lly-getting-somewhat-favorable-media-coverage-analysis-finds/1530019.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with Analyst Ratings Network's FREE daily email newsletter.